Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2662-1347
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer ; volume:3 ; number:9 ; day:5 ; month:8 ; year:2022 ; pages:1138 ; date:9.2022
Nature cancer ; 3, Heft 9 (5.8.2022), 1138, 9.2022
- Urheber
-
Spring, Laura M.
Han, Hyo
Liu, Minetta C.
Hamilton, Erika
Irie, Hanna
Santa-Maria, Cesar A.
Reeves, James
Pan, Peng
Shan, Ming
Tang, Yongqiang
Graham, Julie R.
Hazard, Sebastien
Ellisen, Leif W.
Isakoff, Steven J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s43018-022-00430-w
- URN
-
urn:nbn:de:101:1-2022120921211036738326
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Spring, Laura M.
- Han, Hyo
- Liu, Minetta C.
- Hamilton, Erika
- Irie, Hanna
- Santa-Maria, Cesar A.
- Reeves, James
- Pan, Peng
- Shan, Ming
- Tang, Yongqiang
- Graham, Julie R.
- Hazard, Sebastien
- Ellisen, Leif W.
- Isakoff, Steven J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative PIK3CA-Mutated Advanced Breast Cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative PIK3CA-Mutated Advanced Breast Cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative PIK3CA-Mutated Advanced Breast Cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US